{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-035189","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-09-01T13:00:28+00:00","discovered_at":"2026-09-01T13:02:00.324348+00:00","generated_at":"2026-09-01T13:02:04.339649+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"low","headline":"Gyre Therapeutics posts updated corporate presentation; no new material facts disclosed","bullets":["Company posted updated corporate presentation dated September 2026 on its website on September 1, 2026.","Presentation furnished as Exhibit 99.1; exhibit body text appears truncated in filing, so no specific figures available.","No financial results, guidance, or business developments are disclosed in the furnished exhibit text.","Filing signed by CFO Thomas Eastling."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-035189","json":"https://secwatch.observer/filing/0001140361-26-035189.json","markdown":"https://secwatch.observer/filing/0001140361-26-035189.md","text":"https://secwatch.observer/filing/0001140361-26-035189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/0001140361-26-035189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/ef20081441_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T13:02:04.339649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}